A potential anticancer drug clioquinol inhibits mTOR activity by disrupting the integrity of mTORC1 in multiple myeloma (MM)6, a fatal malignancy of plasma cells that leads to multiple organ dysfunction and universal death. Here, MTOR is linked to AL amyloidosis.